Diversification of funding sources through equity markets, contract revenue, borrowings, and other means
First written in FY2023. 5 of 7 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026-H1.
91 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「Cash provided by financing activities during the current interim accounting period increased by ¥138.349 million, compared with no change in the prior-year interim period. The main factors were proceeds of ¥150 million from long-term borrowings, partly offset by ¥12.501 million in repayments of long-term borrowings.」
The company diversified financing by obtaining ¥150 million in long-term borrowings and recorded a ¥138.349 million increase in financing cash flow after repayments of ¥12.501 million. - 2026-03-27AdvancedManagement Planning
「Funds raised through the first through third issuances of unsecured convertible bonds with share acquisition rights in December 2025 are expected to be allocated to R&D funding and working capital from the fiscal year ending December 2026 onward, including for KP8011 (subacute spinal cord injury),」
The company specified plans to allocate funds raised through convertible bonds with share acquisition rights to R&D funding and working capital for KP8011 and other programs from the fiscal year ending December 2026 onward. - FY2025AdvancedAnnual report
「Cash provided by financing activities during the fiscal year increased by ¥1,496.325 million, compared with no change in the previous fiscal year. The principal factor was proceeds of ¥1,495.975 million from the issuance of bonds.」
The company issued convertible bonds with stock acquisition rights allocated to Alfresa Corporation and secured approximately ¥1.496 billion in financing. - 2026-03-04AdvancedGeneral Meetings of Shareholders
「For the purpose of strengthening mainly the distribution function for investigational products relating to KP8011 (subacute spinal cord injury) in the regenerative medicine business and products to be launched in the future, the company entered into a basic business alliance agreement with アルフレッサ株式会社 in November 2025. It also entered into an investment agreement with the company and secured necessary funds, including future R&D funding, by issuing unsecured convertible bonds with share acquisition rights to be allotted to that company.」
The company entered into a basic business alliance agreement and an investment agreement with アルフレッサ株式会社 and secured ¥1.5 billion through unsecured convertible bonds with share acquisition rights. - FY2025-H1AdvancedAnnual report
「Although proceeds of ¥200 million from short-term borrowings increased funds during the current interim accounting period, the entire amount was repaid during the period, resulting in cash outflows of ¥200 million for repayment of short-term borrowings.」
As an example of indirect financing, the company borrowed ¥200 million on a short-term basis but repaid the full amount during the interim period, resulting in no net change in funds from financing activities. - FY2024RestatedAnnual report
「We will secure stable sources of funds by obtaining financing from the equity markets and subsidies as necessary.」
The company continues to secure financing through equity markets and subsidies while relying primarily on cash on hand. - FY2023First statedAnnual report
「We will diversify the financing methods needed by raising funds in the equity markets, through milestone income linked to business progress and through borrowings from financial institutions.」
The company intends to secure and expand multiple funding sources, including equity markets, milestone income, bank borrowings and subsidies.